Menu Search
Equities

Avricore Health Inc

8VP1:FRA

Avricore Health Inc

Actions
  • Price (EUR)0.107
  • Today's Change-0.002 / -1.83%
  • Shares traded10.00k
  • 1 Year change-14.40%
  • Beta--
Data delayed at least 15 minutes, as of Jun 21 2024 16:04 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Avricore Health Inc. is a pharmacy service company that is focused on acquiring and developing early-stage technologies. The Company is engaged in the business of health data and point-of-care technologies (POCT). It provides digital solutions that support the role of pharmacists and provide infrastructure for making clinical services more accessible and more affordable in its communities. The Company's offering includes HealthTab. HealthTab is a cloud-based network technology that enables the real-time response system where consumers receive a finger-stick blood test at their local pharmacy via a Web-enabled blood chemistry analyzer. Its HealthTab platform can test up to 27 biomarkers on the spot for screening and managing chronic conditions, such as diabetes. It also provides bacterial and viral testing for Strep and COVID-19. The Company's wholly owned subsidiary is HealthTab Inc.

  • Revenue in CAD (TTM)3.98m
  • Net income in CAD-341.17k
  • Incorporated2000
  • Employees--
  • Location
    Avricore Health Inc1120 - 789 West Pender StreetVANCOUVER V6C 1H2CanadaCAN
  • Phone+1 (604) 773-8943
  • Fax+1 (604) 687-2038
  • Websitehttps://avricore.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.